A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

Analysts expect Tesla to report a 5% rise in second-quarter vehicle deliveries, with much of the gain likely to come from ...

Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, ...

Liquid I.V.™ is building on its position as a powdered hydration leader in the UK with launches in Spain, Germany, France, Sweden and Iceland. The expansion supports Liquid I.V.™'s continued growth to ...

The question is why so many technology leaders keep choosing the same place to build and scale.